Polycystic ovary syndrome in Indian women: clinical spectrum and determinants from a regional multicenter study in Vidarbha region, Maharashtra, India

Sushma Deshmukh; Jayashree Shembalkar; Swati Sarda; Rakhi Gajbhiye; Pranita Chitanvis

doi:10.18203/2320-1770.ijrcog20262546

Authors

Sushma Deshmukh Obstetrics and Gynaecology, Deshmukh Hospital, Getwell Multispecialty Hospital and Central India Test Tube Baby Centre, Nagpur, Maharashtra, India
Jayashree Shembalkar Department of Endocrinology, Shembalkar clinic and Getwell Multispecialty Hospital Nagpur, Maharashtra, Indiatral India Test Tube Baby Centre, Nagpur, Maharashtra, India
Swati Sarda Department of Obstetrics and Gynaecology, Shridha Hospital and Research Institute, Nagpur, Maharashtra, India
Rakhi Gajbhiye Department of Obstetrics and Gynaecology, Mauli Women’s Hospital, Nagpur, Maharashtra, India
Pranita Chitanvis Department of Obstetrics and Gynaecology, Ankur Test Tube Baby Centre, Chitnavis Nursing Home and Accident Hospital, Ganesh Nagar, Gondia, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20262546

Keywords:

Adolescents, Infertility, Insulin resistance, Metabolic risk, Obesity, Phenotypes, Polycystic ovary syndrome, Vidarbha

Abstract

Background: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder with reproductive, metabolic, and psychological implications. Despite its high prevalence in Indian women, region-specific data on its clinical and metabolic spectrum remain limited. This study aims to evaluate the clinical presentation, anthropometric markers, metabolic profile, and phenotypic distribution of PCOS among adolescents and infertile women.

Methods: This cross-sectional retrospective, multicenter study was conducted across five centers between January 2022 and January 2023. A total of 309 women aged 14-32 years, diagnosed with PCOS, were enrolled. Data on demographic, reproductive, anthropometric, hormonal, biochemical, and ultrasonographic parameters were collated and analysed.

Results: The mean age of participants was 23.1±5.3 years, with mean menarche at 13.2±1.6 years. Among 153 married women, infertility duration averaged 3.2±2.5 years, with 90% reporting primary infertility. Ovulatory dysfunction was observed in 75.1%, hyperandrogenism in 46.3%, and polycystic ovarian morphology (PCOM) in 50.5%. Acne (46.3%) and acanthosis nigricans (36.2%) were frequent findings. The mean BMI was 25.4±5.3 kg/m², with 73.8% classified as overweight/obese. Neck circumference (33.6±4.0 cm) and wrist circumference (16.7±2.2 cm) showed correlation with insulin resistance. Among adolescents (n=156), hyperandrogenism was present in 55.8%, ovulatory dysfunction in 78%, and 20.5% showed PCOM.

Conclusions: PCOS in Vidarbha women shows early onset, high ovulatory dysfunction, obesity, insulin resistance, and adverse metabolic risks. Age-specific phenotypic variability underscores its evolving nature, necessitating early diagnosis, lifestyle changes, and comprehensive management to reduce reproductive and cardiometabolic complications.

References

Butt MS, Saleem J, Bukhari GMJ, Fischer F. Comparison of physical activity levels and dietary habits between women with polycystic ovarian syndrome and healthy controls of reproductive age: a case-control study. BMC Wom Heal. 2024;24(1):29.

Berni TB, Morgan CL, Rees DA. Rising incidence, health resource utilization, and costs of polycystic ovary syndrome in the United Kingdom. J Clin Endocrinol Metab. 2025;110(5):e1580-9.

Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Revi Endocrinol. 2011;7(4):219-31.

Chaudhari A. Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies. Obesity Medicine. 2023;29:100480.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduct. 2018;33(9):1602-18.

Shukla A, Rasquin LI, Anastasopoulou C. Polycystic Ovarian Syndrome. National Library of Medicine, StatPearls. 2005.

Daniilidis A, Dinas K. Hippokratia. Long term health consequences of polycystic ovarian syndrome: a review analysis. 2009;13(2):90-2.

Helvaci N, Yildiz BO. The impact of ageing and menopause in women with polycystic ovary syndrome. Clin Endocrinol. 2022;97(3):371-82.

Sharma S, Mahajan N. Polycystic ovarian syndrome and menopause in forty plus women. J Mid-life Heal. 2021;12(1):3-7.

Mohapatra I, Samantaray SR. BMI and polycystic ovary syndrome: demographic trends in weight and health. Cureus. 2024;16(3):e55439.

Ganie MA, Chowdhury S, Suri V, Joshi B, Bhattacharya PK, Agrawal S, et al. Prevalence, regional variations, and predictors of overweight, obesity, and hypertension among healthy reproductive-age Indian women: nationwide cross-sectional polycystic ovary syndrome task force study. JMIR Publ Heal Surveill. 2023;9:e43199.

Mandrelle K, Kamath MS, Bondu DJ, Chandy A, Aleyamma TK, George K. Prevalance of metabolic syndrome in women with polycystic ovary syndromeattending an infertility clinic in atertiary care hospital in South India. J Hum Reprod Sci. 2012;5(1):26-31.

Barbosa G, de Sá LB, Rocha DR, Arbex AK. Polycystic ovary syndrome (PCOS) and fertility. Open J Endocri Metabol Dis. 2016;6(01):58.

Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Ind J Medi Res. 2019;150(4):333-44.

Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reproduct Upd. 2016;22(6):687-708.

Rababa’h AM, Matani BR, Yehya A. An update of polycystic ovary syndrome: causes and therapeutics options. Heliyon. 2022 Oct 1;8(10).

Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Coch Data Syst Revi. 2011;7:CD007506.

Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Coch Data System Revi. 2019;3.

Thomson RL, Buckley JD, Brinkworth GD. Perceived exercise barriers are reduced and benefits are improved with lifestyle modification in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial. BMC Wom Heal. 2016;16(1):14.

Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137-45.

Ollila MM, Piltonen T, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, et al. Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: prospective cohort study. J Clin Endocrinol Metab. 2016;101(2):739-47.

Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042.

Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril. 2008;89(3):649-55.

Spritzer P, Barone C, Oliveira F. Hirsutism in polycystic ovary syndrome: pathophysiology and management. Revi Curr Pharm Des. 2016;22(36):5603-5613.

Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, et al. Cutaneous findings and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol. 2016;152(4):391-8.

Chen Y, Zheng X, Ma D, Zheng S, Han Y, Su W, et al. Neck circumference is a good predictor for insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2021;115(3):753-60.

Haapakangas SM, Koskenkari NV, Hurskainen EL, Arffman RK, Ollila MM, Piltonen TT. Neck circumference as a metabolic health marker among women with polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Int J Obes (Lond). 2025;49(6):998-1012.

Chantal A, amassing C, Pozzilli P. Wrist circumference: A new marker for insulin resistance in African women with polycystic ovary syndrome. World J Diabetes. 2020;11(2):42-51.

Yadav S, Tarware R. Waist hip ratio: an anatomical predictive marker of risk of PCOS. Int J Reprod Contracept Obstet Gynecol. 2019;8(4):1630-2.

Šumarac-Dumanović M, Stamenković-Pejković D, Jeremić D, Dumanović J, Mandić-Marković V, Žarković M, et al. Age, body mass index, and waist-to-hip ratio related changes in insulin secretion and insulin sensitivity in women with polycystic ovary syndrome: minimal model analyses. Int J Endocrinol. 2022;2022(1):6630498

Zhu M, Wang K, Feng J, Liu Y, Guan M, Wang Y, et al. The waist-to-height ratio is a good predictor for insulin resistance in women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2024;15:1502321.

Vatopoulou A, Dionelli ME, Papanikolaou A, Grover S. Cardiometabolic risk factors in adolescents with polycystic ovary syndrome. Curr Pharm Design. 2021;27(36):3808-11.

Teede HJ, Tay CT, Laven JJ, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-64.

Rasool SU, Ashraf S, Nabi M, Rashid F, Fazili KM, Amin S. Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome. Diabet Metabol Syndr: Clin Res Revi. 2019;13(3):2098-105.

35. Bushell A, Crespi B. The evolutionary basis of elevated testosterone in women with polycystic ovary syndrome: an overview of systematic reviews of the evidence. Front Reprod Heal. 2024;6:1475132.

Tsuyoshi B. Polycystic ovary syndrome: Criteria, phenotypes, race and ethnicity. Reprod Med Biol. 2025;24(1):e12630.